Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
| Autor: | Nicole Malet, Muriel Laffargue, Fabienne Briand-Mesange, Anne Fougerat, Monique Breton-Douillon, Stéphanie Gayral |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Blood Platelets
Neutrophils T-Lymphocytes Cell Inflammation Pathogenesis Phosphatidylinositol 3-Kinases Immune system Leukocytes medicine Humans PI3K/AKT/mTOR pathway Phosphoinositide-3 Kinase Inhibitors Phosphoinositide 3-kinase biology Kinase business.industry Macrophages General Medicine Atherosclerosis Cell biology medicine.anatomical_structure Immunology biology.protein Cytokines Phosphorylation medicine.symptom business |
| Zdroj: | Clinical Science. 116:791-804 |
| ISSN: | 1470-8736 0143-5221 |
| Popis: | Inflammation has a central role in the pathogenesis of atherosclerosis at various stages of the disease. Therefore it appears of great interest to develop novel and innovative drugs targeting inflammatory proteins for the treatment of atherosclerosis. The PI3K (phosphoinositide 3-kinase) family, which catalyses the phosphorylation of the 3-OH position of phosphoinositides and generates phospholipids, controls a wide variety of intracellular signalling pathways. Recent studies provide evidence for a crucial role of this family not only in immune function, such as inflammatory cell recruitment, and expression and activation of inflammatory mediators, but also in antigen-dependent responses making it an interesting target to modulate inflammatory processes. The present review will focus on the regulation of inflammation within the vasculature during atherogenesis. We will concentrate on the different functions played by each isoform of PI3K in immune cells which could be involved in this pathology, raising the possibility that inhibition of one or more PI3K isoforms may represent an effective approach in the treatment of atherosclerosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|